Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$684.43 USD

684.43
8,362,231

+23.94 (3.62%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $691.03 +6.60 (0.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $598.88, moving -0.07% from the previous trading session.

Andrew Rocco headshot

"Blockbuster Status": 3 Bios to Buy and Hold

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.

Zacks Equity Research

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.

Zacks Equity Research

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

Smart Beta ETF report for FTCS

Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

NVS vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Zacks Equity Research

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Zacks Equity Research

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

Zacks Equity Research

Zacks Investment Ideas feature highlights: IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly

IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly are part of the Zacks Investment Ideas article.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Andrew Rocco headshot

4 Expert Tips for Navigating a Gap Down Market

Investors must learn to thrive in turbulent times. Stock Strategist Andrew Rocco provides 4 ways to hadle "tape bombs"

Zacks Equity Research

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Zacks Equity Research

Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Zacks Equity Research

Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?

Style Box ETF report for EQWL

Zacks Equity Research

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Zacks Equity Research

Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why

Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.

Zacks Equity Research

If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

Zacks Equity Research

The Zacks Analyst Blog Highlights Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE

Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE are included in this Analyst Blog.